Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petra Hoever

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Drugs in R&D|June 6, 2013
Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjectsJasper Dingemanse, Petra Hoever
European Journal of Clinical Pharmacology|January 22, 2013
Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatinMatthias Hoch, Petra Hoever, Rudolf Theodor, et al.
Drug Design, Development and Therapy|May 10, 2014
Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studiesJasper Dingemanse, Martine Gehin, Hans Gabriel Cruz, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 18, 2013
Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonistKasra Shakeri-Nejad, Matthias Hoch, Petra Hoever, et al.
Journal of Pharmaceutical Sciences|March 8, 2014
Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazemJasper Dingemanse, Hans Gabriel Cruz, Martine Gehin, et al.
European Journal of Clinical Pharmacology|September 20, 2012
Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjectsMatthias Hoch, Petra Hoever, Federica Alessi, et al.
Pharmacology|August 26, 2011
Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjectsMatthias Hoch, Petra Hoever, Federica Alessi, et al.
Pharmacology|February 4, 2012
Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjectsMatthias Hoch, Petra Hoever, Jochen Zisowsky, et al.
Journal of Clinical Psychopharmacology|April 24, 2013
Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjectsPetra Hoever, Justin Hay, Mandana Rad, et al.
CNS Drugs|March 15, 2014
Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug usersHans G Cruz, Petra Hoever, Bijan Chakraborty, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Drugs in R&D|June 6, 2013
Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjectsJasper Dingemanse, Petra Hoever
European Journal of Clinical Pharmacology|January 22, 2013
Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatinMatthias Hoch, Petra Hoever, Rudolf Theodor, et al.
Drug Design, Development and Therapy|May 10, 2014
Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studiesJasper Dingemanse, Martine Gehin, Hans Gabriel Cruz, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 18, 2013
Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonistKasra Shakeri-Nejad, Matthias Hoch, Petra Hoever, et al.
Journal of Pharmaceutical Sciences|March 8, 2014
Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazemJasper Dingemanse, Hans Gabriel Cruz, Martine Gehin, et al.
European Journal of Clinical Pharmacology|September 20, 2012
Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjectsMatthias Hoch, Petra Hoever, Federica Alessi, et al.
Pharmacology|August 26, 2011
Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjectsMatthias Hoch, Petra Hoever, Federica Alessi, et al.
Pharmacology|February 4, 2012
Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjectsMatthias Hoch, Petra Hoever, Jochen Zisowsky, et al.
Journal of Clinical Psychopharmacology|April 24, 2013
Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjectsPetra Hoever, Justin Hay, Mandana Rad, et al.
CNS Drugs|March 15, 2014
Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug usersHans G Cruz, Petra Hoever, Bijan Chakraborty, et al.
Pageof 2